top of page

Exploring NGENLA: A New Growth Hormone from Pfizer

NGENLA: A New Era in Growth Hormone Therapy


Pfizer’s NGENLA (somatrogon-ghla) marks a significant advancement in growth hormone therapy, especially for children suffering from growth hormone deficiency (GHD). Unlike traditional treatments such as Genotropin, which requires daily injections, NGENLA offers once-weekly administration, providing comparable efficacy with far greater convenience.


Key Benefits of NGENLA

Somatrogon-ghla is a long-acting recombinant hormone, enhanced through glycosylation, which extends its half-life. By stimulating the production of Insulin-like Growth Factor-1 (IGF-1), it promotes linear growth and helps normalize metabolic functions. The simplified dosing regimen has made it a breakthrough for pediatric GHD patients, reducing injection frequency and treatment burden.

An illustration of NGENLA, a long-acting growth hormone developed by Pfizer, shown alongside Genotropin for dosage comparison.

Discontinuation of Genotropin

Pfizer has stopped the production of Genotropin, which is making it increasingly hard to find genuine stock on the market. The remaining supplies are dwindling, confined mostly to hospital warehouses, and this scarcity has led to a surge in counterfeit products. Many of these fakes are visually identical to the original but lack active ingredients, posing significant risks to users. With Genotropin becoming rarer, patients are turning to alternatives like NGENLA for reliable treatment.


Bodybuilding and NGENLA Dosing Comparison


While NGENLA is designed for medical use in treating growth hormone deficiency, there is off-label interest in using growth hormones like NGENLA and Genotropin in bodybuilding. In bodybuilding, these hormones are valued for their ability to boost muscle repair, increase lean muscle mass, improve metabolism, and reduce fat. Additionally, HGH is said to benefit skin quality and overall appearance.


A typical bodybuilding dose of Genotropin might be 6 IU per day, which totals 42 IU per week. When using NGENLA, the weekly dose would be calculated similarly but administered in one shot. For instance, 42 IU of Genotropin translates to 14 mg of NGENLA once weekly. This makes somatrogon easier and more comfortable to use for those looking for fewer injections, as they can achieve the same hormone level with just one injection per week.






NGENLA and Anti-Aging Therapy


Some individuals seek growth hormones for anti-aging, believing it helps with muscle tone, skin health, and energy. While somatropin (as in Genotropin) and somatrogon (in NGENLA) are sometimes used off-label for these purposes, the risks are not outweigh the potential benefits. Users typically take smaller doses, such as 1-2 IU of Genotropin daily (around 14 IU weekly), and could switch to 4-5 mg of NGENLA weekly. However, the drug is not approved for this purpose.



Conclusion

NGENLA represents a significant improvement in growth hormone therapies with its long-acting, weekly dosing option, especially when compared to older daily-injection therapies like Genotropin. Its convenience and effectiveness make it a vital tool in the management of GHD. However, while some may seek to use NGENLA for off-label purposes such as bodybuilding or anti-aging, it is important to proceed with caution, given the risks associated with use of growth hormones.


It’s important to remember that Genotropin and NGENLA were originally developed to treat children with growth hormone deficiency (GHD). Their primary purpose is medical, focusing on correcting deficiencies that impact growth and development. Over time, some bodybuilders and anti-aging enthusiasts discovered potential benefits in muscle building and recovery, as well as skin health, but these applications are off-label. As the saying goes, "everything is a poison and a remedy - it all depends on the dose," highlighting the importance of using these drugs responsibly.

10 views
bottom of page